Diffusion Pharmaceuticals Inc. (DFFN)
Symbol Info
Listed Symbol DFFN
Name Diffusion Pharmaceuticals Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $-
Latest Fiscal EPS $-8.49
Price Info
21 Day Moving Average $1.8355
21 Day EMA $1.775750
50 Day Moving Average $1.9495
50 Day EMA $1.979980
200 Day EMA $3.221970
200 Day Moving Average 2.895300
52 Week High $11.00
52 Week Low $1.31
52 Week Change $-77.887000
Alpha -0.067698
Beta 0.0594
Standard Deviation 0.242930
R2 0.000070
Periods 60
Share Information
10 Day Average Volume 76,989
20 Day Average Volume 50,539
30 Day Average Volume 47,006
50 Day Average Volume 45,812
Outstanding Shares 4,693,290
Float Shares -
Percent Float -
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 24
Institute Holdings Date 2019-09-30
Institute Bought Previous 3 Months -
Institute Holdings Percent 22.500000
Institute Sold Previous 3 Months 17,393
Insider Holdings Date 2019-08-31
Insider Bought Previous 3 Months 6
Insider Holdings Percent -
Insider Sold Previous 3 Months -
Insiders Shares Owned 8,369,163
Price Change
7 Day Price Change $-0.43
7 Day Percent Change -24.16%
21 Day Price Change $-0.63
21 Day Percent Change -31.82%
30 Day Price Change $-0.7199999
30 Day Percent Change -34.78%
Month To Date Price Change $-0.5
Month To Date Percent -27.03%
90 Day Price Change $-1.17
90 Day Percent Change -46.43%
Quarter To Date $-0.5
Quarter To Date Percent -27.03%
180 Day Price Change $-1.77
180 Day Percent Change -56.73%
200 Day Price Change $-2.3
200 Day Percent Change -63.01%
Year To Date $-0.64
Year To Date Percent -32.16%
Profile
Description Diffusion Pharmaceuticals Inc is a clinical stage biotechnology company. It is focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard-of-care treatments, including radiation therapy and chemotherapy. Its lead product candidate is trans sodium crocetinate (TSC), which is used for the treatment of glioblastoma multiforme (GBM); Phase II pancreatic cancer; and metastatic brain cancer.
Details
Issue Type CS
Market Cap $6,335,942
Sec Type EQS
Auditor KPMG LLP
Total Shares Outstanding 4,693,290
CEO David G. Kalergis
Employees 10
Last Audit UE
Classification
CIK 0001053691
Industry Biotechnology
Sector Healthcare
NAICS Biological Product (except Diagnostic) Manufacturing(325414)
Info
Address 1317 Carlton Avenue
Suite 200
Charlottesville, VA 22902
Website http://www.diffusionpharma.com
Facisimile +1 434 220-0722
Telephone +1 434 220-0718
Email
Key Ratios
Profitability
EBIT Margin -
EBITDA Margin -
Pre-Tax Profit Margin -
Profit Margin Cont -
Gross Margin -
Profit Margin TOT -
Income Statements
Revenue $-
Revenue Per Share $-
Revenue 3 Years $-
Revenue 5 Years $-
Valuation Measures
PE Ratio -
Enterprise Value $601,694
Price To Sales -
Price To Free Cash -1
PE High Last 5 Years -
Price To Book 0.5
Price To Cash Flow -
PE Low Last 5 Years -
Price To Tangible Book 1.1
Financial Strength
Total Debt To Equity 0.0
Int Coverage -117.4
Current Ratio 9.0
Leverage Ratio 1.2
Quick Ratio 8.0
Long Term Debt To Capital 0.01
Assets
Receivables Turnover -
Invoice Turnover -
Assets Turnover -
Management Effectiveness
Return Assets -71.75
Return On Equity -80.66
Return On Capital -79.59
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
DFFN
Diffusion ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.